

Code No. 18582

## Anti-Human Amyloidβ (1-42) Rabbit IgG Affinity Purify

Volume : 50 μg

Introduction

: Alzheimer's Disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein components of these plaques are beta amyloid peptide (A $\beta$ ), 40, 42 or 43 amino acid residues peptide cleaved from amyloid precursor protein by  $\beta$ -secretase and  $\gamma$ -secretase. Increased release of A $\beta$ 42 or A $\beta$ 43, which have a greater tendency to aggregate than A $\beta$ 40, occurs in individuals expressing certain genetic mutations ApoE alleles or may involve other undiscovered factors. Many researchers theorize that increased release of A $\beta$ 42/A $\beta$ 43 leads to the abnormal deposition of A $\beta$  and the associated neurotoxicity in the brains of affected individuals.

**Antigen**: Synthetic peptide of a C-terminal part of Human Amyloidβ42

Purification : Affinity Purified with synthetic peptide

Form : Lyophilized product in PBS containing 1 % BSA and 0.05 % NaN<sub>3</sub>

How to use : 0.5 mL deionized water will be added to the product (the concentration will

become 100 µg/mL).

**Stability**: Lyophilized product, 5 years at 2 – 8 °C

: Solution, 2 years at -20 °C

**Application**: This antibody can be used for immunohistochemistry with formalin fixed paraffin

embedded tissues after formic acid treatment $^{*1}$ . The recommended concentration is 1 - 5  $\mu$ g/mL, however, the concentration should be optimized by

each laboratory.

\*1; Soak in formic acid for 5 minutes after de-paraffin step, and rinse by running

water

: This antibody can be used for western blotting in concentration of 5 µg /mL.

**Specificity**: Human Amyloidβ42 specific.

Not cross-react with Human Amyloidβ40 or 43.